AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

75 76 Next >

AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript ↗

February 08, 2024

AZN earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 08, 2024

Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.

Via Benzinga

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month ↗

February 08, 2024

Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.

Via Investor's Business Daily

Earnings Scheduled For February 8, 2024 ↗

February 08, 2024

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.

Via Benzinga

Earnings Outlook For AstraZeneca ↗

February 07, 2024

Via Benzinga

Check Out What Whales Are Doing With AZN ↗

January 17, 2024

Via Benzinga

AstraZeneca Stock Tumbles After Q4 Performance - Here's Why ↗

February 08, 2024

AstraZeneca Q4 2023: $12.02 billion sales, 7% Y/Y growth, fueled by global demand for cancer drugs. Excluding COVID-19 meds, revenue rises 16%. CEO Soriot projects low double-digit growth in 2024.

Via Benzinga

AstraZeneca Downgraded On "Underwhelming" Q4 Earnings ↗

February 08, 2024

AZN stock took a header early Thursday after a mixed Q4 report and a downgrade to sell on "thoroughly underwhelming" results.

Via Investor's Business Daily

AstraZeneca Full year and Q4 2023 Financial Results

February 08, 2024

From AstraZeneca

Via Business Wire

AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

February 06, 2024

From AstraZeneca

Via Business Wire

NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment? ↗

February 05, 2024

The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs.

Via InvestorPlace

Markets suddenly price Eli Lilly stock for a breakout on earnings

February 05, 2024

The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up

Via MarketBeat

Topics Bonds Economy

History Says the Nasdaq Will Keep Soaring in 2024. Here's the Surprising Megacap Stock Wall Street Thinks Will Be the Biggest Winner. ↗

February 03, 2024

Hint: It's not Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, or Tesla.

Via The Motley Fool

Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗

February 02, 2024

The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.

Via Benzinga

Topics Economy

Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares ↗

January 31, 2024

Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market.

Via Benzinga

3 No-Brainer Stocks to Buy With $500 Right Now ↗

January 31, 2024

A reasonably modest amount of money can go a long way when it's put to work in industry-leading businesses.

Via The Motley Fool

Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60% ↗

January 30, 2024

Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.

Via Benzinga

Pfizer’s earnings growth trade at a deep discount, suddenly a buy

January 29, 2024

The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite

Via MarketBeat

Topics Economy

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors

January 29, 2024

From AstraZeneca

Via Business Wire

3 Magnificent Stocks to Buy and Hold Forever ↗

January 27, 2024

Many investors will want to consider owning these stocks for a long time.

Via The Motley Fool

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗

January 23, 2024

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.

Via Benzinga

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

January 22, 2024

From AstraZeneca

Via Business Wire

Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy ↗

January 20, 2024

Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech...

Via Talk Markets

AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study ↗

January 19, 2024

Explore results from AstraZeneca's EMERALD-1 Phase 3 trial on Imfinzi for unresectable hepatocellular carcinoma. Statistically significant improvement in progression-free survival with Imfinzi plus...

Via Benzinga

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

January 19, 2024

From AstraZeneca

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

January 16, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold ↗

January 15, 2024

Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value.

Via InvestorPlace

MarketBeat Week in Review – 1/8 - 1/12

January 13, 2024

Stocks drifted lower as the latest inflation numbers are dampening expectations for a rate cut; here are some of our top stories for your long weekend

Via MarketBeat

Topics ETFs Economy

Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst ↗

January 12, 2024

Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed...

Via Benzinga

NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution

January 12, 2024

Via Investor Brand Network

Topics Intellectual Property

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.